1. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017; 152:313–321.
2. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134:929–936.
3. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximaband immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012; 107:1051–1063.
4. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015; 21:182–197.
5. Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and alternative medicines used by patients with inflammatory bowel diseases. Gastroenterology. 2017; 152:415–429.
6. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003; 98:1563–1568.
7. Li FX, Verhoef MJ, Best A, Otley A, Hilsden RJ. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol. 2005; 19:567–573.
8. Nguyen GC, Croitoru K, Silverberg MS, Steinhart AH, Weizman AV. Use of complementary and alternative medicine for inflammatory bowel disease is associated with worse adherence to conventional therapy: the COMPLIANT Study. Inflamm Bowel Dis. 2016; 22:1412–1417.
9. Rawsthorne P, Clara I, Graff LA, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut. 2012; 61:521–527.
10. Gallinger ZR, Nguyen GC. Practices and attitudes toward complementary and alternative medicine in inflammatory bowel disease: a survey of gastroenterologists. J Complement Integr Med. 2014; 11:297–303.
11. Hung A, Kang N, Bollom A, Wolf JL, Lembo A. Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Dig Dis Sci. 2015; 60:1883–1888.
12. Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf. 2004; 27:773–797.
13. Cheung F. TCM: made in China. Nature. 2011; 480:S82–S83.
14. Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract. 2012; 66:924–939.
15. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Defining relapse of ulcerative colitis using a symptombased activity index. Scand J Gastroenterol. 2003; 38:164–171.
16. Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006; 12:304–310.
17. Bensoussan M, Jovenin N, Garcia B, et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol. 2006; 30:14–23.
18. Weizman AV, Ahn E, Thanabalan R, et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther. 2012; 35:342–349.
19. Portela F, Dias CC, Caldeira P, et al. The who-when-why triangle of CAM use among Portuguese IBD patients. Dig Liver Dis. 2017; 49:388–396.
20. Abitbol V, Lahmek P, Buisson A, et al. Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey. Eur J Gastroenterol Hepatol. 2014; 26:288–294.
21. Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B. Use of complementary and alternative medicine in Germany: a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006; 6:19.
22. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med. 2007; 15:30–37.
23. Park DI, Cha JM, Kim HS, et al. Predictive factors of complementary and alternative medicine use for patients with inflammatory bowel disease in Korea. Complement Ther Med. 2014; 22:87–93.
24. Lee SH, Chang K, Seo KS, et al. Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey. Intest Res. 2020; 18:192–199.
25. Leong RW, Lawrance IC, Ching JY, et al. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci. 2004; 49:1672–1676.
26. Stadlbauer V, Fickert P, Lackner C, et al. Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol. 2005; 11:4758–4760.
27. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther. 2003; 18:451–471.
28. Park HL, Lee HS, Shin BC, et al. Traditional medicine in china, Korea, and Japan: a brief introduction and comparison. Evid Based Complement Alternat Med. 2012; 2012:429103.
29. Torres J, Ellul P, Langhorst J, et al. European Crohn’s and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis. 2019; 13:673–685e.
30. Langhorst J, Wulfert H, Lauche R, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis. 2015; 9:86–106.
31. Norton C, Czuber-Dochan W, Artom M, Sweeney L, Hart A. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 46:115–125.
32. Koning M, Ailabouni R, Gearry RB, Frampton CM, Barclay ML. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study. Inflamm Bowel Dis. 2013; 19:767–778.